114 results on '"Perez, Lia Elena"'
Search Results
2. JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results
3. Outcomes of Haploidentical Stem Cell Transplant Recipients with HHV-6 Reactivation Receiving Antiviral Therapy
4. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
5. Expanded Antigen-Specific Donor Regulatory T Cells for Gvhd Prevention
6. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation
7. Impact of Obesity and Chemotherapy Dosing on Allogeneic Hematopoietic Cell Transplant Outcomes for Myelodysplastic Syndrome (MDS)
8. Developing Contemporary Survivorship Clinic for Recipients of Hematopoietic Cell Transplantation: A Single Center Experience
9. Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
10. The Effect of Mycophenolate Mofetil Dose per Kilogram on Outcomes of Haploidentical Donor Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide
11. Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
12. Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-Versus-Host Disease
13. Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma
14. Multivirus-Specific T-Cell Therapy with Posoleucel (ALVR105) for Refractory Disseminated Adenovirus Infection after Allogeneic HCT
15. Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting
16. Prospective Cohort Study of Immune Suppression Taper and Discontinuation
17. Measurable Residual Disease Outcompetes Cytogenetics in Predicting Leukemia Free Survival Following Allogeneic Stem Cell Transplantation Outcomes in Adults with Acute Lymphoblastic Leukemia
18. Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel in Multiple Myeloma
19. CD40 Ligand Blockade Prevents Acute Gvhd: Results from a Multicenter Phase I-Ib Trial
20. Allogeneic Hematopoietic Cell Transplant Outcomes for Chronic Myelomonocytic Leukemia: Single Center Experience
21. Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Patients
22. 490 - Developing Contemporary Survivorship Clinic for Recipients of Hematopoietic Cell Transplantation: A Single Center Experience
23. 437 - Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
24. 363 - The Effect of Mycophenolate Mofetil Dose per Kilogram on Outcomes of Haploidentical Donor Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide
25. 265 - Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
26. 140 - Impact of Obesity and Chemotherapy Dosing on Allogeneic Hematopoietic Cell Transplant Outcomes for Myelodysplastic Syndrome (MDS)
27. 122 - Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-Versus-Host Disease
28. A Phase II Study of Sirolimus-Based Calcineurin Inhibitor-Free Gvhd Prophylaxis after Peripheral Blood Haploidentical Transplantation with Post-Transplant Cyclophosphamide
29. Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia – a Single Institution Experience
30. The Effect of Mycophenolate Mofetil Dose per Kilogram on Clinical Outcomes of Allogeneic Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide
31. Phase II Multicenter Study of Ofatumumab in Combination with Glucocorticoids As a Primary Therapy for Chronic Graft Versus Host Disease
32. Delayed CD4+ T-Cell but Faster B-Cell Immune Reconstitution after Ptcy-Based Compared to Conventional Gvhd Prophylaxis after Allogeneic Transplantation
33. 499 - Multivirus-Specific T-Cell Therapy with Posoleucel (ALVR105) for Refractory Disseminated Adenovirus Infection after Allogeneic HCT
34. 451 - Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma
35. 403 - CD40 Ligand Blockade Prevents Acute Gvhd: Results from a Multicenter Phase I-Ib Trial
36. 405 - Prospective Cohort Study of Immune Suppression Taper and Discontinuation
37. 241 - Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting
38. 243 - Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel in Multiple Myeloma
39. 167 - Measurable Residual Disease Outcompetes Cytogenetics in Predicting Leukemia Free Survival Following Allogeneic Stem Cell Transplantation Outcomes in Adults with Acute Lymphoblastic Leukemia
40. Survival of Older Patients with AML and MDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices
41. ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
42. 162 - Allogeneic Hematopoietic Cell Transplant Outcomes for Chronic Myelomonocytic Leukemia: Single Center Experience
43. 55 - Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Patients
44. Reduced Intensity Fludarabine/Melphalan Has Similar Survival to Myeloablative Fludarabine/Busulfan (Targeted) in Patients with AML and MDS
45. Predictors of Non-Relapse Mortality Among Patients Treated with Sirolimus- Vs. Non-Sirolimus-Containing Immune Suppression for Graft-Versus-Host Disease Prevention
46. IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease
47. Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft Vs. Host Disease
48. 398 - Reduced Intensity Fludarabine/Melphalan Has Similar Survival to Myeloablative Fludarabine/Busulfan (Targeted) in Patients with AML and MDS
49. High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation Early during the Course of Disease Appears to Improve Outcomes of Patients T Cell Non-Hodgkin Lymphoma: Results of a Single-Institution Experience
50. Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.